Acquired Bleeding Disorder Clinical Trial
Official title:
A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass
This trial is conducted in Africa, Asia, Europe, South America and the United States of
America (USA).
The trial is planned to investigate the safety and efficacy of NovoSeven® in the management
of post-operative bleeding in patients following cardiac surgery.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01601457 -
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
|
Phase 2 | |
| Completed |
NCT00124293 -
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
|
N/A | |
| Completed |
NCT02239146 -
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
|
Phase 1 | |
| Terminated |
NCT00184548 -
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
|
Phase 3 | |
| Completed |
NCT01563445 -
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
|
Phase 2 | |
| Withdrawn |
NCT00323570 -
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
|
Phase 3 | |
| Completed |
NCT00127283 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 3 | |
| Completed |
NCT01563523 -
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
|
Phase 2 | |
| Terminated |
NCT01564563 -
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT01153997 -
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
|
Phase 1 | |
| Completed |
NCT00697320 -
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
|
N/A | |
| Completed |
NCT00914589 -
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
|
Phase 2 | |
| Completed |
NCT00102037 -
Use of Activated Recombinant FVII in Spinal Surgery
|
Phase 2 | |
| Completed |
NCT01601613 -
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
|
Phase 2 | |
| Completed |
NCT01562821 -
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
|
Phase 2 | |
| Completed |
NCT00266006 -
Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 2 | |
| Completed |
NCT00123591 -
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
|
Phase 2 | |
| Completed |
NCT01562574 -
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
|
Phase 3 | |
| Completed |
NCT01285089 -
Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
|
N/A | |
| Completed |
NCT00426803 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 2 |